Advertisement

Clinical and Translational Oncology

, Volume 7, Issue 1, pp 3–11 | Cite as

A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer

  • Eduardo Díaz-Rubio García
  • Albert Abad Esteve
  • Antonio Antón Torres
  • Enrique Aranda Aguilar
  • Manuel Benavides Orgaz
  • Alfredo Carrato Mena
  • Andrés Cervantes Ruipérez
  • Jaime Feliu Batle
  • Pilar García Alfonso
  • Jesús García Foncillas
  • Cristina Garávalos Castro
  • Matilde Navarro García
  • Fernando Rivera Herrero
  • José María Tabernero Caturla
Reviews
  • 41 Downloads

Abstract

Current issues of adjuvant therapy for colon cancer concern the introduction of drugs other than fluorouracil-5/leucovorin (5-FU/LV), the benefits for stage II patients, the use of new primary endpoints and the influence of age on treatment benefits. These issues were addressed in a panel discussion and the conclusions were the following: FOLFOX4 is the first regimen that shows superiority over 5-FU/LV. The use of 3-year disease-free survival as primary endoint could encourage the quicker adoption of improved therapeutic strategies into clinical practice. Available data suggest that there are some benefits for stage II patients, and the decision needs to be individualised for each patient. Further, therapeutic decisions based solely on the patient's age are inappropriate, and geriatric assessment tools will help in making this decision. This information would improve patient and physician understanding of the recent data regarding the potential benefits of adjuvant therapy.

Keywords

adjuvant treatment colon cancer 

Discusión de expertos sobre controversias y retos en el tratamiento adyuvante del

Resumen

Las controversias actuales referentes al tratamiento adyuvante del cáncer de colon incluyen la introducción de fármacos más allá de 5-FU/LV, el beneficio que ofrece a los pacientes con estadio II, el uso de nuevas variables y la influencia de la edad sobre los beneficios del tratamiento. Estas controversias fueron discutidas en un panel de expertos y las conclusiones fueron las siguientes: FOLFOX4 es el primer régimen que ha demostrado superioridad frente a 5-FU/LV. El uso de la supervivencia libre de enfermedad a 3 años como variable principal de los estudios podrá permitir una adopción más répida de estrategias terapéuticas. Los datos disponibles sugieren que existe beneficio para los pacientes con estadio II, y la decisión terapéutica debe ser individualizada. Finalmente, también se llegó a la conclusión de que las decisiones basadas únicamente en la edad no son apropiadas, y las herramientas de valoración geriátrica servirán de apoyo. Esta información puede mejorar el entendimiento de pacientes y médicos acerca de los datos recientes relativos a los beneficios del tratamiento adyuvante.

Palabras clave

tratamiento adyuvante cancer de colon 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mcdonald JS, Astrow AB. Adjuvant therapy of colon cancer. Semin Oncol 2001;28:30–40.Google Scholar
  2. 2.
    Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447–56.PubMedGoogle Scholar
  3. 3.
    Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321–6.PubMedGoogle Scholar
  5. 5.
    Zoetmulder FAN, Taal BG, van Tinteren H on behalf of the, NACCP. Adjuvant 5FU plus levamisole improves survival in stage II and III colonic cancer, but not in rectal cancer. Interim analysis of the Netherlands Adjuvant Colorectal Cancer Project (NACCP) [abstract]. Proc Am Soc Clin Oncol 1999;18:266a.Google Scholar
  6. 6.
    O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246–50.PubMedGoogle Scholar
  7. 7.
    Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994;106:899–906.PubMedGoogle Scholar
  8. 8.
    Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7: 1407–18.PubMedGoogle Scholar
  9. 9.
    De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808–15.PubMedGoogle Scholar
  10. 10.
    Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003;21:2896–903.PubMedCrossRefGoogle Scholar
  11. 11.
    De Gramont A, Tournigand C, Louvet C, et al. Oxaliplatin, folinic acid and 5-fluorouracic (folfox) in pretreated patients with metastatic advancer cancer. The GERCOD. Rev Med. Interne 1997;18:769–75.Google Scholar
  12. 12.
    De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47.PubMedGoogle Scholar
  13. 13.
    Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059–69.PubMedCrossRefGoogle Scholar
  15. 15.
    Topham C, Boni C, Navarro M, et al. Multicenter international randomized study of oxaliplatin/5FU/LV (fol-fox) in stage II and III colon cancer (MOSAIC trial): final results. Eur J Cancer Suppl 2003;1:S324.CrossRefGoogle Scholar
  16. 16.
    Buyse M, Zeleniuch-Jacquott A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988;24:3571–8.CrossRefGoogle Scholar
  17. 17.
    International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939–44.CrossRefGoogle Scholar
  18. 18.
    Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988;80:30–6.PubMedCrossRefGoogle Scholar
  19. 19.
    O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989;63(6 Suppl):1026–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990;8: 1466–75.PubMedGoogle Scholar
  21. 21.
    O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295–300.PubMedGoogle Scholar
  22. 22.
    Sargent D, Wieand S, Benedetti J, et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12.915 patients on 15 randomized trials [abstract]. Proc Am Soc Clin Oncol 2004;22:3502a.Google Scholar
  23. 23.
    Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995;13:2936–43.PubMedGoogle Scholar
  24. 24.
    International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:1356–63.Google Scholar
  25. 25.
    Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997;89:497–505.CrossRefGoogle Scholar
  26. 26.
    NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;26:1444–50.Google Scholar
  27. 27.
    Taal BG, Van Tinteren H, Zoetmulder FAN on behalf of the NACCP group. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001;85:1437–43.PubMedCrossRefGoogle Scholar
  28. 28.
    Moamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dikes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C03, and C-04). J Clin Oncol 1999;17:1349–55.Google Scholar
  29. 29.
    Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001;28(Suppl 1):20–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345: 1091–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Quinn MJ, d'Onofrio A, Moller B, et al. Cancer mortality trends in the EU and acceding countries up to 2015. Ann Oncol 2003;14:1148–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94:2766–92.PubMedCrossRefGoogle Scholar
  33. 33.
    Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Nalt Cancer Inst 2001;93:850–7.CrossRefGoogle Scholar
  34. 34.
    Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002;136:349–57.PubMedGoogle Scholar
  35. 35.
    Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 1996;124:577–84.PubMedGoogle Scholar
  36. 36.
    Colorectal Cancer Collaborative Group. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 2000;356:968–74.CrossRefGoogle Scholar
  37. 37.
    Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999 17:2412–8.PubMedGoogle Scholar
  38. 38.
    Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Ate and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11–7.PubMedCrossRefGoogle Scholar

Copyright information

© FESEO 2005

Authors and Affiliations

  • Eduardo Díaz-Rubio García
    • 1
  • Albert Abad Esteve
    • 2
  • Antonio Antón Torres
    • 3
  • Enrique Aranda Aguilar
    • 4
  • Manuel Benavides Orgaz
    • 5
  • Alfredo Carrato Mena
    • 6
  • Andrés Cervantes Ruipérez
    • 7
  • Jaime Feliu Batle
    • 8
  • Pilar García Alfonso
    • 9
  • Jesús García Foncillas
    • 10
  • Cristina Garávalos Castro
    • 11
  • Matilde Navarro García
    • 12
  • Fernando Rivera Herrero
    • 13
  • José María Tabernero Caturla
    • 14
  1. 1.Service of Medical OncologyHospital Universitario San CarlosMadridSpain
  2. 2.Service of Medical OncologyHospital Universitari Germans Trias i Pujol. BadalonaBarcelonaSpain
  3. 3.Service of Medical OncologyHospital Miguel ServetZaragozaSpain
  4. 4.Service of Medical OncologyHospital Reina SofiaCórdobaSpain
  5. 5.Service of Medical OncologyHospital General Carlos HayaMálagaSpain
  6. 6.Service of Medical OncologyHospital General Universitario de ElcheElche. AlicanteSpain
  7. 7.Service of Medical OncologyHospital Clínico UniversitarioValenciaSpain
  8. 8.Service of Medical OncologyCiudad Sanitaria La PazMadridSpain
  9. 9.Service of Medical OncologyHospital General Universitario Gregorio MarañónMadridSpain
  10. 10.Laboratory of Biotechnology and PharmacogenomicsClínica Universitaria de NavarraPamplonaSpain
  11. 11.Service of Medical OncologyHospital Universitario 12 de OctubreMadridSpain
  12. 12.Service of Medical Oncology. Institut Català d'Oncologia (ICO)L'Hospitalet de LlobregatBarcelonaSpain
  13. 13.Service of Medical OncologyHospital Universitario Marqués de ValdecillaSantanderSpain
  14. 14.Service of Medical OncologyHospital General Vall d'HebronBarcelonaSpain

Personalised recommendations